Johnson & Johnson (JNJ) Monday said that Health Canada authorized Lazcluze in combination with Rybrevant for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC).
The Health Canada Notice of Compliance (NOC) is based on results from the Phase 3 MARIPOSA study, which showed Lazcluze plus Rybrevant reduced the risk of disease progression or death by 30 per cent compared with osimertinib in the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations.
"With this authorization, Lazcluze plus Rybrevant becomes the first and only chemotherapy-free combination regimen showing clinically meaningful and statistically significant improvement in progression-free survival versus osimertinib for these patients," the company said in a statement.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.